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In spite a of significant reduction in total and cardiac
arrhythmic mortality in post- myocardial infarction pa-
tients, ventricular arrhythmias still account for 30-40%
of deaths. This figure, which was initially provided by
studies carried out in the pre-thrombolytic era, has
been  subsequently  confirmed  in  patients  in  whom
revascularization  was  obtained  by  means  of  either
thrombolysis or percutaneous coronary intervention
(PCI) (1, 2).
Early and effective reperfusion and a more gener-
alised use of beta blockers, ACE inhibitors, statines
and anti-platelet agents have largely contributed to
improve prognosis in patients with ST elevated my-
ocardial infarction. Nevertheless, a still unacceptable
number of patients die within two years from the index
event and the mortality rate is even greater when my-
ocardial infarction is complicated by a marked de-
pression of left ventricular function. To deal with this
problem, identification of patients at risk, which is
rarely made in day to day clinical practice, should be-
come one of the most important features of patient
management (2). 
There is a general consensus that depressed ventric-
ular function as reflected by a left ventricular ejection
fraction (LVEF) < 40% represents the strongest negative
prognostic factor in these post-myocardial patients (1,
2). The relative simplicity of computation and the fact
that almost all patients with an acute myocardial infarc-
tion have a two-dimensional echocardiographic evalua-
tion before discharge, have largely contributed to this
practice. Different cut-off values have been proven ef-
fective in recent clinical trials and a LVEF<30% has
been used as single inclusion criteria in studies aiming
to evaluate, for example, the beneficial effect of im-
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plantable cardioverter defibrillator (ICD) after MI. After
the publication of MADIT II results (3) that have clearly
indicated a significant reduction in total and arrhythmic
mortality in post-myocardial infarction patients with ICD
in comparison to controls, ICD implantation has been
recommended for almost all post-myocardial infarction
patients with a LVEF < 30%. This position has only been
partially accepted by the most recent ACC/AHA/NASPE
and ESC guidelines (4, 5) but has been recently called
into discussion after the publication of the results of the
Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)
(6). This study has demonstrated that ICD prophylaxis
can improve survival in patients selected primarily by a
substantially reduced LVEF. It must be pointed out how-
ever, that the absolute benefit of ICD prophylaxis on
mortality is relatively small in both studies (5.6% or
7.2%) which based patient selection only on LVEF. As a
consequence, one could speculate that only a few ICD’s
implanted prophylactically deliver appropriate therapy
and reduce arrhythmic mortality, thus providing an in-
complete answer to this major clinical problem. 
Efficacy of ICD in patients with acute myocar-
dial infarction
The beneficial effect of ICD in patients discharged af-
ter an acute MI is even more controversial when consid-
ering with accuracy the results of published studies.
This issue has been the object of renewal interest after
the publication of the results of the DINAMIT study (7).
More than six hundred patients with a recent acute my-
ocardial infarction and reduced left ventricular function
(LVEF< 35%) were randomised to ICD or control on the
top of best medical therapy. Revascularization (either
by means of thrombolysis or PCI) was performed in
about 62% of patients. During a one year follow-up pe-
riod, prophylactic ICD therapy did not reduce overall
mortality in this high risk population. Moreover, by con-
sidering type of death, it became evident that the re-
duction in the rate of death due to arrhythmia was offset
by an increase in the rate of death from non arrhythmic
causes.
A careful comparison of the study design and patient
characteristics of the MADIT II and DINAMIT studies
provides a partial explanation for such a difference.
Whereas in MADIT II, the mean time to enrollment after
the index event was 81 months, in DINAMIT all patients
were randomized within 6-40 days from the acute event.
Thus, timing of implantation in relation to the index
event appears to be the factor that could explain the dif-
ference in the efficacy results. Indeed, by reviewing a
recent report by MADIT II authors (8), the lack of benefit
from ICD implantation is detectable when considering
patients with a less remote myocardial infarction (<18
months), whereas a tendency for a favourable effect or
a  definite  and  significant  benefit  becomes  evident
thereafter and, in particular, from 60 to > 120 months af-
ter the acute event. 
One could therefore extrapolate that, according to the
DINAMIT and MADIT II studies and at variance with our
expectations, the benefit from prophylactic ICD implan-
tation is barely detectable in the first two years after an
acute myocardial infarction. Further doubts as to the
recommendation of an early ICD implantation in all post-
myocardial infarction patients with a depressed LVEF are
a logical consequence of the above findings (9).
Timing of arrhythmic death after myocardial
infarction
The lack of benefit from ICD implantation in the first
two years after an acute myocardial infarction could be
interpreted in two different ways: first, that available da-
ta are inadequate to draw definitive conclusions and ad-
ditional  studies  are  necessary;  second,  that  in  the
reperfusion era, the risk of arrhythmic death becomes
predominant and plays a major role only after several
months from the acute event. This latter point had been
recently addressed by two studies that have provided
consistent information.
YAP and co-workers (10) have accurately described
the temporal trends of arrhythmic versus non arrhyth-
mic deaths after an acute myocardial infarction. In this
retrospective study, data were retrieved from the place-
bo limbs of five major studies carried out in the throm-
bolytic era on high risk post-myocardial infarction pa-
tients according to presence of either a depressed ven-
tricular function (LVEF <40%) or ambient ventricular ar-
rhythmias (>10 ventricular premature beats/hour or a
run of non sustained ventricular tachycardia at 24 hour
Holter monitoring). The main conclusion of the study
was that the overall risk of arrhythmic death from eitherArrhythmic death and ICD implantation after myocardial infarction
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the index event or day 45 after MI was persistently high-
er than that of non arrhythmic death and that this trend
did not change over time in a 2-year follow-up period.
Moreover, the absolute risk of both arrhythmic and non-
arrhythmic death was higher in the first six months after
MI and decreased with time.
Similar results were reported by Scott and co-work-
ers (11) who studied 14,609 patients with left ventricular
dysfunction or heart failure after an acute myocardial in-
farction. Seven percent of patients had an event a me-
dian of 180 days after myocardial infarction: 903 died
suddenly, and 164 were resuscitated after cardiac ar-
rest. The risk was highest in the first 30 days after the in-
dex event and decreased slowly thereafter. Patients
with LVEF <30% were at highest risk in this early period.
Nineteen percent of all sudden deaths or episodes of
cardiac arrest with resuscitation occurred within the
first 30 days after myocardial infarction and 83% of all
patients who died suddenly did so in the first 30 days
after discharge. It was also found that each decrease of
5 percentage points in LVEF was associated with a 21%
adjusted increase in the risk of sudden death or cardiac
arrest with resuscitation in the first 30 days.
These dramatic results, which are consistent with
previous reports (1, 2) and common clinical experience,
unequivocally demonstrate the presence of a higher ar-
rhythmic risk in the first months after an acute myocar-
dial infarction and oblige performing an early stratifica-
tion for the evaluation of the arrhythmic risk in each pa-
tient with a ST elevated acute myocardial infarction. On-
ly thereafter, an ICD implantation should be taken into
consideration if supported by the guidelines (4, 5).
Timing of arrhythmic death and ICD efficacy
But why do ICD trials in post-myocardial infarction
patients fail to demonstrate a clear benefit in the time
frame when the risk of arrhythmic death is greater? The
results of the DINAMIT study (7), as pointed out above,
provide some answers to this question. The authors re-
ported that in ICD carriers, there was indeed a reduction
of arrhythmic mortality in the time frame characterised
by greatest risk of arrhythmic death but this benefit was
offset by an increase in non arrhythmic mortality. It has
been hypothesised that patients saved from arrhythmic
death might die, and to a greater extent than controls,
from other cardiac causes (7). If this interpretation is
correct, one could draw the conclusion that in the reper-
fusion era, the presence of a markedly depressed left
ventricular function might be less effective in identifying
arrhythmic risk, patients with a LVEF < 30% also being
at higher risk of death from other cardiac causes. In-
deed, data from the MUSST study (12) confirm that
ejection fraction by itself does not discriminate between
modes of deaths, whereas inducible tachy-arrhythmias
identify patients for whom death, if it occurs, is signifi-
cantly more likely to be arrhythmic especially if the ejec-
tion fraction is >30%.
Following upon these data, one could put into dis-
cussion the traditional interpretation according to which
risk stratification has to be mainly or solely performed in
patients with a reduced LVEF. By doing so, it is possible
that on one hand, we only switch the type of death in
very sick patients without prolonging life, on the other
we do not provide adequate protection against arrhyth-
mic risk in patients with a relatively preserved LVEF in
whom arrhythmic risk is not trivial and prophylactic ICD
implantation could be of benefit.
How to identify patients at risk?
If LVEF is not adequate to identify patients with an in-
creased arrhythmic risk after an acute myocardial in-
farction, are there any other parameters which can be
used in the clinical setting? Evaluation of autonomic
tone has been utilised to improve risk stratification in
patients enrolled in the DINAMIT study (7). Unfortunate-
ly, SDNN (standard deviation of normal RR intervals),
i.e. the most accepted prognostic parameter of heart
rate variability (13-17), failed to identify patients with
greater arrhythmic risk. This negative finding could be
partially explained by the fact that measures of auto-
nomic tone such as SDNN or baroreflex sensitivity are
inversely correlated with age and LVEF. For these rea-
sons, they are less effective when used to evaluate ar-
rhythmic risk in patients with depressed left ventricular
function (13-17). 
More recently, in order to identify post-myocardial in-
farction patients with increased arrhythmic risk and
possible benefit from ICD therapy, other non invasive
parameters known to reflect alterations of ventricular
electrical properties such as QRS duration, ventricularLombardi
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late potential or microvolt T-wave alternans (MTWA)
have been the object of investigation (17). Hohnloser et
al (18) identified 129 patients with LVEF <30% from two
previously published clinical trials in which MTWA was
prospectively assessed within two months after an
acute myocardial infarction. At follow-up, no sudden
cardiac death or cardiac arrest was observed in patients
with a negative test, whereas an event rate of 15.6%
was detected in patients with abnormal MTWA. A recent
report by Bloomfield et al (8) provides additional sup-
port to the potential value of this methodology in the
identification of patients at risk after a remote myocar-
dial infarction. These authors studied 177 MADIT II like
patients. Abnormal QRS duration (>120 msec) and MT-
WA were detected in, respectively, 32 and 68% of pa-
tients. Patients with an abnormal MTWA had a 2-year
actuarial mortality rate of 17.8% whereas patients with
a normal test had a very low mortality rate (3.2%). QRS
duration did not add any significant additional prognos-
tic information.
A recent report (19) from the same authors extended
previous observations and provided additional results.
The study enrolled 549 patients with LVEF <40% and no
history of sustained ventricular arrhythmias. One half of
the patients had a previous and remote myocardial in-
farction (5 year average time). During a two year follow-
up 51 end points (40 deaths and 11 non fatal sustained
ventricular arrhythmia) were observed. Comparing pa-
tients with normal and abnormal MTWA tests, the haz-
ard ratio for the primary endpoint was 6.5 at two years.
Survival of patients with normal MTWA test was 97.5%
at two years. All the above findings indicate that MTWA
testing was highly effective in identifying two subgroups
of patients: those at high risk for arrhythmic event and
those who will not experience ventricular tachy-arrhyth-
mia and thus, not likely to benefit from ICD implantation. 
It must be noticed that whereas MTWA testing ap-
pears appropriate to identify high and low risk sub-
groups of MADIT-II or SCD-HeFT like patients, more
controversial remains the definition of the predictive
value of MTWA testing in the early months after an
acute myocardial infarction, i.e. in the time frame char-
acterized by the highest risk of arrhythmic mortality.
It has been proposed (20) that MTWA may predict
outcome if measured at least 30 days after the acute
event; results, however, are not unequivocal. For exam-
ple, Ikeda et al (21) showed that positive MTWA mea-
sure 2.7±5.4 months after myocardial infarction predict-
ed sudden cardiac death or resuscitated ventricular fib-
rillation. However, when MTWA testing was performed
(17) before discharge (eight days) in patients with a rel-
atively preserved LVEF, it failed to predict mortality. A
similar negative result was reported by Schwab et al
(22) who measured MTWA 15±5 days after an acute my-
ocardial infarction in patients with a LVEF >40%. A par-
tial explanation of these contradictory findings is due to
the fact that as a consequence of changes in cardiac
electro-mechanical  properties  due  to  remodelling, 
MTWA testing results evolve from the first days to the
first weeks after the acute event with a 67% concor-
dance. This pattern of change and poor reproducibility
in the first weeks after the acute event prevent the pos-
sibility of using what appears to be the most sensitive
indicator of arrhythmic risk for routine stratification be-
fore hospital discharge.
CONCLUSIONS
The finding that in post-myocardial infarction patients
with LVEF <40% or frequent VPB the risk of arrhythmic
death is superior to that of non arrhythmic death for up
to two years after the acute event, has important clinical
implications in relation to risk stratification and identifi-
cation of patients who can benefit from ICD implanta-
tion. Recent clinical studies, however, indicate that if pa-
tients are stratified only according to a reduced LVEF,
ICD therapy has little effect on overall mortality. This de-
rives from the fact that the reduction in arrhythmic mor-
tality is counterbalanced by an increase in non arrhyth-
mic cardiac mortality. It is therefore to be hoped that in
the near future, the evaluation of individual risk profile
will not be limited to the determination of the extent of
left ventricular function but will be combined with the
analysis of other risk markers such as those reflecting
autonomic dysfunction, cardiac electrical instability and
presence of subclinical inflammation (23).
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